Presented at #ESMO26:
In a prespecified interim analysis of a phase 3 trial involving patients with extensive-stage SCLC, the median overall survival was 21.1 months with tarlatamab–durvalumab maintenance therapy and 12.7 months with durvalumab alone. Full DeLLphi-305 trial results: https://t.co/9dEqH6apj2
@myESMO
Study presented at #ESMO26, from our collaboration with @pfizer, evaluated more than 60,000 advanced #NSCLC cases and found greater than 80% sensitivity across all 12 biomarkers using routine H&E pathology images.
Read on: https://t.co/GsPw5ih824